CRISPR Therapeutics AG

Sector and Industry

Healthcare, Biopharmaceuticals

Performance (1Y)

25.73%

Market Cap

-

P/E Ratio

0.00

Dividend Yield

0.00 %

Earnings per Share

-5.73 €

Peer Group

Company NameMarket CapRevenue Last Reported YearP/E RatioProfit Growth 1YLast PricePrevious Trading Day Change
Eli Lilly and Company864.54 Bil.57.78 Bil.46.82
+86.88 %
0.00
-
Johnson & Johnson425.70 Bil.83.48 Bil.18.82
+82.71 %
0.00
-
AbbVie Inc.343.94 Bil.54.21 Bil.96.78
-5.29 %
0.00
-
Roche Holding AG286.62 Bil.65.80 Bil.20.72
+58.45 %
0.00
-
AstraZeneca PLC244.91 Bil.52.09 Bil.27.55
+39.41 %
0.00
-
NOVARTIS AG 224.76 Bil.48.44 Bil.18.30
+12.45 %
0.00
-
Merck & Co. Inc.221.79 Bil.57.55 Bil.14.46
+2.25 %
0.00
-
Novo-Nordisk AS B193.52 Bil.41.49 Bil.14.11
+1.54 %
0.00
-
Amgen Inc.150.16 Bil.32.57 Bil.23.01
+80.77 %
0.00
-
Gilead Sciences Inc.129.70 Bil.26.10 Bil.18.10
+1,599.93 %
0.00
-

Facts & figures

Price data

TRADE PLATFORMBörse Stuttgart (XSTU)
LAST PRICE45.96 G0 Units
PRICE DETERMINATION TIME06/17/2026 / 09:57:19 PM
DAILY VOLUME (UNITS)390
DAILY HIGH / LOW47.3644.35
PREV. DAY'S PRICE44.76 (06/16)
CHANGE DAY BEFORE
+1.20
2.68 %
52 WEEK HIGH / LOW67.5 (10/08)35.2 (06/17)
More Price Information

Key Figures (in EUR)

2027e2026e202520242023
EARNINGS PER SHARE-3.11-4.16-5.73-4.01-1.79
DIVIDENDS PER SHARE0.000.000.000.000.00
DIVIDEND YIELD IN %--0.00 %0.00 %0.00 %
DIVIDEND GROWTH IN %-----
PRICE - EARNINGS RATIO-----
PRICE - BOOK RATIO--2.621.752.66
PRICE - SALES RATIO--1,343.5088.9813.36
PRICE - CASH FLOW RATIO-----
Further Key Figures

Master Data

WKN
A2AT0Z
ISIN
CH0334081137
SYMBOL
1CG
EXCHANGE SEGMENT
Freiverkehr
TYPE OF FINANCIAL INSTRUMENT
Equity
DENOMINATION
CRISPR THERAPEUT. SF -,03
INDEX MEMBERSHIP
-
TRADING SEGMENT
-
TRADING HOURS
07:30:00 AM - 10:00:00 PM
TRADING CURRENCY
Euro
NOMINAL CURRENCY
-
SETTLEMENT CURRENCY
Euro
SECTOR AND INDUSTRYHealthcare, Biopharmaceuticals
NUMBER OF SHARES
-
MARKET CAPITALISATION
-

Performance overview

1W1M3M6M1Y3Y5YYTD
PERFORMANCE
0.42 %
7.58 %
6.57 %
-4.77 %
25.73 %
--
-3.95 %
HIGH45.7450.3050.3052.5067.50--52.50
LOW42.5140.5038.0038.0035.20--38.00
Dividend
per share
CRISPR THERAPEUT. SF -,03 does not deliver dividend information

Company profile

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Shareholder Structure (Top 10)

AnteilName
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available

Analyst Rating

Ø-Target Price DistanceNot Available
Current Price
Not Available
Ø-Target Price
Not Available
Average ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0

Company Events

No company events available.